Log in Free sign up

Sierra Oncology (SRRA) News and press releases

News

From Benzinga Pro

The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease

Biotech, Large Cap, News, Penny Stocks, Health Care, Small Cap, FDA, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Sierra Oncology's Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting On June 7, 10:33 a.m.

Biotech, News, Events, General

Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the

Recap: Sierra Oncology Q1 Earnings

Sierra Oncology (NASDAQ:SRRA) reported its Q1 earnings results on Friday, May 6, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Sierra Oncology Q1 EPS $(1.33) Up From $(1.46) YoY

Sierra Oncology (NASDAQ:SRRA) reported quarterly losses of $(1.33) per share. This is a 8.9 percent increase over losses of $(1.46) per share from the same period last year.

The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More

Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, General

Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting season.

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Analyst Ratings for Sierra Oncology

Analyst Ratings

Sierra Oncology (NASDAQ:SRRA) has observed the following analyst ratings within the last quarter:

Analyzing Sierra Oncology Inc's Short Interest

Short Sellers, Short Ideas, Trading Ideas

Sierra Oncology Inc's (NASDAQ:SRRA) short percent of float has fallen 10.32% since its last report. The company recently reported that it has 1.21 million shares sold short, which is 11.91% of all regular shares that are available for trading.

Jefferies Downgrades Sierra Oncology to Hold, Raises Price Target to $55

News, Downgrades, Price Target, Analyst Ratings

Jefferies analyst Maury Raycroft downgrades Sierra Oncology (NASDAQ:SRRA) from Buy to Hold and raises the price target from $39 to $55.

Oppenheimer Downgrades Sierra Oncology to Perform, Raises Price Target to $55

News, Downgrades, Price Target, Analyst Ratings

Oppenheimer analyst Jay Olson downgrades Sierra Oncology (NASDAQ:SRRA) from Outperform to Perform and raises the price target from $45 to $55.

12 Health Care Stocks Moving In Wednesday's Intraday Session

Sierra Oncology Stock Is Soaring: Here's Why

M&A, Small Cap, Movers, Trading Ideas

Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in cash, representing an a

Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

HC Wainwright & Co. Downgrades Sierra Oncology to Neutral, Raises Price Target to $55

News, Downgrades, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Joseph Pantginis downgrades Sierra Oncology (NASDAQ:SRRA) from Buy to Neutral and raises the price target from $51 to $55.

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More

Biotech, M&A, News, Penny Stocks, Health Care, Small Cap, FDA, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal

Biotech, M&A, News, Health Care, Small Cap, Movers, Trading Ideas, General

GSK Reached Agreement to Acquire Sierra Oncology For $55/Share

M&A, News, Small Cap

GlaxoSmithKline plc (LSE/NYSE: GSK) and Sierra Oncology, Inc (Nasdaq: SRRA) today announced that the companies have entered into an agreement under which GSK will acquire Sierra Oncology, a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for $55 pe

Press releases

From Benzinga Pro

Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration

– Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare

Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting

– MOMENTUM data demonstrate potential use of momelotinib in myelofibrosis patients who are symptomatic and anemic – – Additional data highlight improved transfusion independence, symptoms and spleen volume of cytopenic

Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting

– Oral presentation of MOMENTUM pivotal phase 3 data in myelofibrosis patients who are symptomatic and anemic – – Poster presentation to highlight improved transfusion independence, symptoms and spleen volume of these

Sierra Oncology Reports First Quarter 2022 Results

Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the first

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates BKI, SAIL, SRRA, ATRS

News, Legal, Press Releases

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary

SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Sierra Oncology, Inc (NASDAQGM:SRRA) to GlaxoSmithKline plc

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CMPI, SBOW, SRRA, ATRS

Small Cap, Press Releases

NEW YORK, May 3, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to

The M&A Class Action Firm Continues the Investigation of Sierra Oncology, Inc. - SRRA

M&A, Press Releases

NEW YORK, NY / ACCESSWIRE / May 2, 2022 /Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated

SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA

Kuznicki Law PLLC is investigating the proposed sale of Sierra Oncology, Inc (NASDAQGM:SRRA) to GlaxoSmithKline plc (NYSE:GSK). Under the terms of the proposed transaction, shareholders of Sierra will receive only

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates SBOW, SAIL, SRRA, VWTR

Legal, Press Releases

NEW YORK, NY / ACCESSWIRE / April 29, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary

SHAREHOLDER ALERT: Weiss Law Reminds SRRA, HBP, EMCF, and VWTR Shareholders About Its Ongoing Investigations

NEW YORK, April 28, 2022 /PRNewswire/ -- If you own shares in any of the companies listed above and

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates PLAN, WAVD, SRRA, ATRS

NEW YORK, April 28, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties

SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Sierra Oncology, Inc (NASDAQGM:SRRA) to GlaxoSmithKline plc

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates TVTY, SRRA, ATRS, VWTR

Legal, Press Releases

NEW YORK, NY / ACCESSWIRE / April 21, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary

SHAREHOLDER ALERT: Weiss Law Reminds ATRS, SRRA, HBP, and EMCF Shareholders About Its Ongoing Investigations

NEW YORK, April 20, 2022 /PRNewswire/ -- If you own shares in any of the companies listed above and

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CDK, TUFN, SAIL, SRRA

News, Legal, Press Releases

NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary

Investor Alert - The M&A Class Action Firm is Investigating the Merger - ATRS, SRRA, SAIL, MSP, CDK, VWTR

NEW YORK, April 18, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Sierra Oncology, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - April 18, 2022) - Rigrodsky Law, P.A. is investigating Sierra Oncology, Inc. ("Sierra") (NASDAQ:SRRA) regarding possible breaches of fiduciary duties and other violations of law

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates VWTR, ATRS, SBOW, SRRA

NEW YORK , April 18, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary

Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing

Small Cap, Opinion, Press Releases

PALM BEACH, Fla., April 14, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - CAR-T therapy is a sort of treatment in which a patient's T cells which is a type of immune system cell, are genetically